Skip to main content

Table 5 Subgroup analysis on the association between methylation and OS a

From: DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

SymbolSubgroupUnivariate CoxMultivariate CoxPropensity score-1Propensity score-2
Crude HR (95%CI)P valueAdjusted HR b (95%CI)P valueAdjusted HR b (95%CI)P valueAdjusted HR c (95%CI)P value
SFRP2Age
  < 45 years-old0.150 (0.020–1.148)0.0680.021 (0.001–0.348)0.0070.126 (0.016–1.025)0.0530.161 (0.021–1.263)0.082
  ≥ 45 years-old0.346 (0.160–0.748)0.0070.414 (0.188–0.911)0.0280.479 (0.221–1.035)0.0610.537 (0.246–1.173)0.119
Gender
 Male0.373 (0.149–0.935)0.0350.357 (0.135–0.945)0.0380.471 (0.186–1.197)0.1130.551 (0.213–1.427)0.219
 Female0.214 (0.066–0.698)0.0110.311 (0.091–1.056)0.0610.328 (0.098–1.102)0.0710.291 (0.085–1.005)0.051
Tumor location
 Colon0.177 (0.043–0.733)0.0170.120 (0.027–0.527)0.0050.203 (0.049–0.843)0.0280.215 (0.052–0.899)0.035
 Rectum0.413 (0.178–0.960)0.0400.570 (0.237–1.366)0.2070.673 (0.291–1.557)0.3550.722 (0.308–1.695)0.455
TNM Staging
 I-II0.372 (0.132–1.048)0.0610.375 (0.126–1.119)0.0790.442 (0.156–1.254)0.1250.428 (0.150–1.221)0.112
 III-IV0.311 (0.113–0.859)0.0240.280 (0.097–0.809)0.0190.374 (0.133–1.048)0.0610.452 (0.160–1.272)0.132
Postoperative chemotherapy
 No0.249 (0.078–0.797)0.0190.284 (0.085–0.945)0.0400.381 (0.117–1.239)0.1090.365 (0.111–1.203)0.098
 Yes0.360 (0.142–0.910)0.0310.392 (0.150–1.026)0.0560.448 (0.177–1.130)0.0890.535 (0.207–1.384)0.197
SFRP1+ SFRP2Age
  < 45 years-old0.150 (0.020–1.148)0.0680.021 (0.001–0.348)0.0070.119 (0.014–1.025)0.0530.151 (0.019–1.225)0.077
  ≥ 45 years-old0.334 (0.155–0.720)0.0050.399 (0.181–0.879)0.0230.463 (0.212–1.008)0.0520.523 (0.238–1.152)0.108
Gender
 Male0.356 (0.143–0.886)0.0260.339 (0.130–0.884)0.0270.448 (0.179–1.119)0.0860.526 (0.206–1.343)0.179
 Female0.214 (0.066–0.698)0.0110.311 (0.091–1.056)0.0610.328 (0.098–1.103)0.0720.304 (0.090–1.022)0.054
Tumor location
 Colon0.177 (0.043–0.733)0.0170.120 (0.027–0.527)0.0050.200 (0.048–0.832)0.0270.213 (0.051–0.890)0.034
 Rectum0.397 (0.172–0.918)0.0310.546 (0.227–1.312)0.1760.656 (0.278–1.551)0.3370.708 (0.297–1.690)0.437
TNM Staging
 I-II0.372 (0.132–1.048)0.0610.375 (0.126–1.119)0.0790.445 (0.157–1.260)0.1270.434 (0.152–1.237)0.118
 III-IV0.295 (0.108–0.809)0.0180.263 (0.092–0.751)0.0130.352 (0.127–0.970)0.0440.419 (0.147–1.193)0.103
Postoperative chemotherapy
 No0.249 (0.078–0.797)0.0190.284 (0.085–0.945)0.0400.381 (0.117–1.239)0.1090.360 (0.109–1.191)0.094
 Yes0.343 (0.137–0.861)0.0230.372 (0.144–0.961)0.0410.426 (0.168–1.076)0.0710.517 (0.200–1.332)0.172
  1. aAll HR values were referenced by hypomethylation
  2. bControlling for the variables which included age, gender, CEA, CA19–9, TNM staging, pathological classification, differentiation degree and postoperative radiotherapy
  3. cControlling for the variables which included age, gender, CEA, CA19–9, multiple polyps, tumor location, TNM staging, pathological classification, histologic classification, differentiation degree, postoperative chemotherapy and postoperative radiotherapy